TNSN08515A1 - 2-phenyl-indoles as prostaglandin d2 receptor antagonists - Google Patents

2-phenyl-indoles as prostaglandin d2 receptor antagonists

Info

Publication number
TNSN08515A1
TNSN08515A1 TNP2008000515A TNSN08515A TNSN08515A1 TN SN08515 A1 TNSN08515 A1 TN SN08515A1 TN P2008000515 A TNP2008000515 A TN P2008000515A TN SN08515 A TNSN08515 A TN SN08515A TN SN08515 A1 TNSN08515 A1 TN SN08515A1
Authority
TN
Tunisia
Prior art keywords
accompanied
diseases
itch
urticaria
inflammation
Prior art date
Application number
TNP2008000515A
Other languages
English (en)
Inventor
Zhaoxia Yang
Stephan Reiling
Thaddeus R Nieduzak
Rose M Mathew
Sharon Jackson
Keith J Harris
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TNSN08515A1 publication Critical patent/TNSN08515A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
TNP2008000515A 2006-07-25 2008-12-12 2-phenyl-indoles as prostaglandin d2 receptor antagonists TNSN08515A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82029906P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25
PCT/US2007/073945 WO2008014186A1 (en) 2006-07-25 2007-07-20 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number Publication Date
TNSN08515A1 true TNSN08515A1 (en) 2010-04-14

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000515A TNSN08515A1 (en) 2006-07-25 2008-12-12 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Country Status (25)

Country Link
US (1) US20090176804A1 (cg-RX-API-DMAC7.html)
EP (1) EP2066628B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009544721A (cg-RX-API-DMAC7.html)
KR (1) KR20090039735A (cg-RX-API-DMAC7.html)
AR (1) AR062051A1 (cg-RX-API-DMAC7.html)
AT (1) ATE485270T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007276885A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714554A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659055A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190511A2 (cg-RX-API-DMAC7.html)
CR (1) CR10577A (cg-RX-API-DMAC7.html)
DE (1) DE602007010010D1 (cg-RX-API-DMAC7.html)
DK (1) DK2066628T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099087A (cg-RX-API-DMAC7.html)
GT (1) GT200900016A (cg-RX-API-DMAC7.html)
IL (1) IL196587A0 (cg-RX-API-DMAC7.html)
MA (1) MA30643B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009000830A (cg-RX-API-DMAC7.html)
NO (1) NO20090862L (cg-RX-API-DMAC7.html)
PE (1) PE20080549A1 (cg-RX-API-DMAC7.html)
PT (1) PT2066628E (cg-RX-API-DMAC7.html)
TN (1) TNSN08515A1 (cg-RX-API-DMAC7.html)
TW (1) TW200821286A (cg-RX-API-DMAC7.html)
WO (1) WO2008014186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072576A1 (ja) * 2007-12-04 2009-06-11 Sapporo Breweries Limited 骨形成促進剤
RS52809B (sr) * 2008-11-17 2013-10-31 F. Hoffmann-La Roche Ag. Naftilsirćetne kiseline
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
PH12016501764B1 (en) 2014-03-17 2024-05-17 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CN112384497A (zh) 2018-05-09 2021-02-19 格卢科克斯生物科技有限公司 具有选择性nox抑制活性的新型磺酰胺衍生物
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
PE20080549A1 (es) 2008-06-20
ECSP099087A (es) 2009-02-27
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31
DE602007010010D1 (de) 2010-12-02
JP2009544721A (ja) 2009-12-17
CL2007002163A1 (es) 2008-02-08
EP2066628B1 (en) 2010-10-20
BRPI0714554A2 (pt) 2013-05-07
KR20090039735A (ko) 2009-04-22
IL196587A0 (en) 2009-11-18
MA30643B1 (fr) 2009-08-03
CA2659055A1 (en) 2008-01-31
ATE485270T1 (de) 2010-11-15
TW200821286A (en) 2008-05-16
EP2066628A1 (en) 2009-06-10
MX2009000830A (es) 2009-02-03
AU2007276885A1 (en) 2008-01-31
DK2066628T3 (da) 2011-02-07
CO6190511A2 (es) 2010-08-19
US20090176804A1 (en) 2009-07-09
GT200900016A (es) 2010-10-13
NO20090862L (no) 2009-02-24
AR062051A1 (es) 2008-08-10

Similar Documents

Publication Publication Date Title
MY157036A (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
MX2008011369A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2.
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ECSP099087A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
TNSN08131A1 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
EP1486491A4 (en) CARBOXYLIC ACID COMPOUNDS AND COMPOUND-CONTAINING MEDICAMENTS AS ACTIVE INGREDIENT
UA88472C2 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
ECSP067057A (es) Nuevos derivados de piridazin-3(2h)-ona
AU2012316912A8 (en) Novel heterocyclic derivatives and their uses
NO20024281L (no) Indolderivater, fremgangsmÕte for fremstilling av de samme og anvendelse derav
WO2007146838A3 (en) Substituted phenyl acetic acids as dp-2 antagonists
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
TW200635932A (en) New pyridothienopyrimidine derivatives
EP1666473A4 (en) CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT
UA95303C2 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
DOP2009000009A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
WO2007046022A3 (en) Inhibitors of phosphodiesterase type-iv